Medidata took a look at how eCRF design complexity correlates with the number of migrations performed while a study is actively collecting subject data.
Quite often, during the course of a clinical trial, the need arises to update case report forms (CRFs). In the world of electronic data capture, these forms are electronic, or “eCRFs.” Such updates can arise from protocol amendments, changes to the eCRF specification requirements or to the logic that automates the entry or verification of data in the study. Creating a new version of the eCRF and migrating subject records to that version is time consuming and costly, and can add additional burden-not only to sponsor and CRO personnel but also to sites. It is therefore imperative to keep such eCRF updates and migrations to the necessary minimum.
With this in mind, we took a look at how eCRF design complexity correlates with the number of migrations performed while a study is actively collecting subject data. Our expectation was that a correlation exists, and this was confirmed by the data. As you can see in the graph, the more complex the eCRF design the more likely it was to require an update during the course of the study. The eCRF design complexity is based on the number of unique eCRF pages, edit checks (custom and standard) and derivations included in the design. The studies included in the dataset were grouped based on their eCRF design complexity and the average number of migrations performed per study. Our findings indicated that the studies with the highest eCRF complexity also performed more migrations, which results in more time spent maintaining the eCRFs.
The study-planning phase should take into account factors that will affect eCRF design efficiency. Having a lower eCRF design complexity will have a positive downstream effect by mitigating the need for migrations and lessening burden on study teams and site staff during the course of the study.
-Medidata Solutions
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.